Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eli Lilly and : to Use Dexcom's Continuous Glucose Monitoring Devices

share with twitter share with LinkedIn share with facebook
share via e-mail
12/16/2019 | 07:13am EST

By Dave Sebastian

Eli Lilly & Co. (LLY) said it has struck an agreement with DexCom to use Dexcom products in Lilly's currently developed personalized diabetes management system.

Under the non-exclusive agreement, Lilly said Monday it would use Dexcom's continuous glucose monitoring devices in both the pen- and pump-based platforms of the system.

The pen-based platform aims to integrate personalized data from a prefiled, disposable insulin pen with data from glucose-sensing technologies into a compatible software application, Lilly said.

Lilly said the pump-based platform is a hybrid-closed-loop system that would automate insulin dosing by integrating an insulin pump, continuous glucose monitor and a handheld controller or smartphone application that controls the system.

Write to Dave Sebastian at dave.sebastian@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
DEXCOM, INC. 12.57% 283.91 Delayed Quote.29.79%
ELI LILLY AND COMPANY -0.48% 141.12 Delayed Quote.7.37%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND COMPANY
02/13ELI LILLY AND COMPANY : Ex-dividend day for
FA
02/11ELI LILLY AND : Lilly Announces Topline Results for Solanezumab from the Dominan..
AQ
02/11EAGLE PHARMACEUTICALS : Receives final fda approval for pemfexy
AQ
02/11ELI LILLY AND : Gets Canada Approval for Taltz in Ankylosing Spondylitis
DJ
02/10Health Care Up As Risk Appetite Boosts Biotech -- Health Care Roundup
DJ
02/10Lilly, Roche Drugs Fail to Halt Inherited Form of Alzheimer's -- 2nd Update
DJ
02/10Lilly, Roche Drugs Fail to Halt Inherited Form of Alzheimer's -- Update
DJ
02/10Lilly, Roche Drugs Fail to Stymie Inherited Form of Alzheimer's
DJ
02/10ELI LILLY AND : Lilly to Participate in Guggenheim Healthcare Talks Idea Forum
AQ
02/10LILLY, GENENTECH : Study in Rare Form of Alzheimer's Misses Main Endpoint
DJ
More news
Financials (USD)
Sales 2020 23 964 M
EBIT 2020 7 401 M
Net income 2020 5 485 M
Debt 2020 10 799 M
Yield 2020 2,06%
P/E ratio 2020 22,4x
P/E ratio 2021 17,6x
EV / Sales2020 6,10x
EV / Sales2021 5,71x
Capitalization 135 B
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 146,80  $
Last Close Price 141,12  $
Spread / Highest target 19,0%
Spread / Average Target 4,02%
Spread / Lowest Target -19,9%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Myles Oneill Senior VP & President-Manufacturing Operations
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY7.37%135 494
JOHNSON & JOHNSON2.92%395 123
ROCHE HOLDING AG8.47%294 912
NOVARTIS4.05%220 633
MERCK AND COMPANY-9.13%210 426
PFIZER-6.81%202 051